Document is current
Any future updates will be listed below
-
Authors
Wang, Chenliang
Zhu, Ming
Bao, Lei
Toffessi Tcheuyap, Vanina
Brugarolas, James
Luo, Weibo
Wang, Yingfei
-
Funding
Funding for this research was provided by:
National Cancer Institute (P50196516)
U.S. Department of Defense (HT9425-24-1-0702)
U.S. Department of Defense (HT9425-24-1-0703)
- License Information
-
More Information
Article History
Received: 4 February 2026
Accepted: 18 May 2026
First Online: 9 June 2026
Declarations
Ethics approval and consent to participate: Animal studies were approved and conducted under the oversight of the UT Southwestern Institutional Animal Care and Use Committee. Human ccRCC PDX tumors were approved by the Institutional Review Board at UT Southwestern Medical Center with written informed consent and generated as described previously [ ].
Consent for publication: Not Applicable.
Competing interests: JB reports personal fees from Arrowhead Pharmaceuticals, Calithera, Eisai, Exelixis, Johnson and Johnson, and Telix outside the submitted work. JB has patents/applications pertaining to HIF2. None of these activities are related or relevant to the work presented herein. Other authors declare that they have no competing interests.
